STOCK TITAN

Talaris Therapeutics Inc - tals STOCK NEWS

Welcome to our dedicated news page for Talaris Therapeutics (Ticker: tals), a resource for investors and traders seeking the latest updates and insights on Talaris Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Talaris Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Talaris Therapeutics's position in the market.

Rhea-AI Summary
Talaris announces results of special meeting and plans for merger with Tourmaline Bio
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
-
Rhea-AI Summary
Talaris Therapeutics declares special dividend in connection with merger
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends acquisition
-
Rhea-AI Summary
Talaris Therapeutics and Tourmaline Bio have announced a merger to create a Nasdaq-listed biotechnology company focused on developing anti-IL-6 antibody TOUR006. The combined company will have approximately $210 million in cash, supporting three clinical trials for TOUR006. Talaris stockholders will receive $3.43 per share and 21.3% of the combined company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.73%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.39%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
conferences
Talaris Therapeutics Inc

Nasdaq:TALS

TALS Rankings

TALS Stock Data

119.57M
4.21M
11.91%
77.66%
0.77%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About TALS

talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.